Theracryf Plc (FRA:8EV)

Germany flag Germany · Delayed Price · Currency is EUR
0.0005
0.00 (0.00%)
At close: Nov 28, 2025
Market Cap4.62M
Revenue (ttm)n/a
Net Income (ttm)-2.32M
Shares Outn/a
EPS (ttm)-0.00
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volumen/a
Open0.0005
Previous Close0.0005
Day's Range0.0005 - 0.0005
52-Week Range0.0005 - 0.0200
Betan/a
RSI48.15
Earnings DateDec 3, 2025

About Theracryf

Theracryf Plc, a clinical stage therapeutics company, engages in the development of therapeutics for oncology and behavioural brain disorders. The company develops orexin-1 antagonist for the treatment of binge eating disorder and anxiety; and atypical dopamine transporter inhibitor (DAT) to treat fatigue and narcolepsy. It also develops SFX-01 for the treatment of brain cancer glioblastoma and neurodevelopmental disorders. The company was formerly known as Evgen Pharma plc and changed its name to Theracryf Plc in April 2024. Theracryf Plc was ... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2014
Employees 9
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 8EV
Full Company Profile

Financial Performance

Financial numbers in GBP Financial Statements

News

There is no news available yet.